Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy
Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G.
Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines the rationale for developing new combined therapeutic approaches, and describes the state of the art of the various potential strategies and the promising research perspectives.